Patriot Financial Group Insurance Agency LLC Has $636,000 Stake in Voyager Therapeutics, Inc. (NASDAQ:VYGR)

Patriot Financial Group Insurance Agency LLC trimmed its position in Voyager Therapeutics, Inc. (NASDAQ:VYGR) by 18.0% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 112,198 shares of the company’s stock after selling 24,696 shares during the quarter. Patriot Financial Group Insurance Agency LLC owned about 0.21% of Voyager Therapeutics worth $636,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds also recently bought and sold shares of the company. China Universal Asset Management Co. Ltd. lifted its position in shares of Voyager Therapeutics by 64.1% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 10,489 shares of the company’s stock worth $61,000 after purchasing an additional 4,098 shares during the last quarter. Intech Investment Management LLC acquired a new position in shares of Voyager Therapeutics during the third quarter worth approximately $74,000. Hsbc Holdings PLC bought a new stake in shares of Voyager Therapeutics in the second quarter valued at approximately $128,000. SG Americas Securities LLC grew its stake in shares of Voyager Therapeutics by 86.7% in the fourth quarter. SG Americas Securities LLC now owns 23,044 shares of the company’s stock worth $131,000 after acquiring an additional 10,704 shares during the last quarter. Finally, Verition Fund Management LLC bought a new position in Voyager Therapeutics during the third quarter worth $216,000. 48.03% of the stock is currently owned by institutional investors.

Voyager Therapeutics Price Performance

Shares of NASDAQ:VYGR opened at $5.60 on Wednesday. The stock has a market capitalization of $305.93 million, a price-to-earnings ratio of 7.89 and a beta of 0.93. The business’s fifty day moving average price is $5.81 and its two-hundred day moving average price is $6.58. Voyager Therapeutics, Inc. has a fifty-two week low of $4.99 and a fifty-two week high of $10.66.

Voyager Therapeutics (NASDAQ:VYGR) last announced its earnings results on Tuesday, November 12th. The company reported ($0.16) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.29. The business had revenue of $24.63 million during the quarter, compared to analysts’ expectations of $12.63 million. Voyager Therapeutics had a net margin of 15.80% and a return on equity of 8.33%. During the same quarter last year, the company posted ($0.59) EPS. Research analysts expect that Voyager Therapeutics, Inc. will post -0.91 EPS for the current fiscal year.

Analyst Ratings Changes

VYGR has been the topic of several research analyst reports. Canaccord Genuity Group restated a “buy” rating and issued a $14.00 price target on shares of Voyager Therapeutics in a research report on Thursday, November 14th. Leerink Partners started coverage on Voyager Therapeutics in a research report on Wednesday, October 16th. They set an “outperform” rating and a $15.00 target price on the stock. Wedbush assumed coverage on Voyager Therapeutics in a report on Friday, November 29th. They issued an “outperform” rating and a $11.00 price target for the company. HC Wainwright reiterated a “buy” rating and issued a $30.00 price objective on shares of Voyager Therapeutics in a research report on Monday. Finally, Citigroup assumed coverage on Voyager Therapeutics in a research report on Monday, December 2nd. They set a “buy” rating and a $12.00 price objective on the stock. One equities research analyst has rated the stock with a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus price target of $15.97.

Insider Transactions at Voyager Therapeutics

In other Voyager Therapeutics news, COO Robin Swartz sold 6,500 shares of the stock in a transaction dated Monday, December 23rd. The shares were sold at an average price of $5.65, for a total transaction of $36,725.00. Following the sale, the chief operating officer now owns 112,328 shares of the company’s stock, valued at $634,653.20. This represents a 5.47 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders have sold 10,778 shares of company stock valued at $58,548 in the last three months. 4.53% of the stock is owned by corporate insiders.

About Voyager Therapeutics

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.